Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
USA-based neuroscience company Cortex Pharmaceuticals (OTCBB: CORX) and privately held biotech firm Pier Pharmaceuticals say they have consummated a merger in an all-stock transaction, with Pier becoming a wholly-owned subsidiary of Cortex, effective August 10, 2012. 15 August 2012
Generics
Indian drugmaker Sun Pharmaceutical Industries (SUN: BO) says that it has now reached agreement to acquire Israel-based Taro Pharmaceutical Industries (PinkSheets: TAROF), after the former increased its offer price. 14 August 2012
Biotechnology
US cancer drug developer MEI Pharma (Nasdaq: MEIP) has entered into a definitive asset purchase agreement with Singapore's privately-held biotech firm S*BIO Pte to acquire the latter's exclusive worldwide rights to pracinostat, an investigational, potential best-in-class, oral histone deacetylase (HDAC) inhibitor. 8 August 2012
Pharmaceutical
Japanese drugmaker Fuji Pharma says it has entered into an agreement with Switzerland's DKSH to acquire OLIC, Thailand's the largest contract pharmaceutical manufacturer, with the aim of expanding its business outside Japan. 7 August 2012
Pharmaceutical
Making its third acquisition this year, USA-based OPKO Health (NYSE: OPK) said on Friday that it has bought Farmadiet Group Holding, a Barcelona, Spain-based company currently engaged in the development, manufacture, marketing and sale of pharmaceutical, nutraceutical and veterinary products. 5 August 2012
Generics
Italian drugmaker Recordati (RC: MI) said yesterday that it has signed an agreement to acquire 100% of the share capital of Farma-Projekt Sp zoo, a Polish pharmaceutical company with headquarters in Krakow. 3 August 2012
article
UK-based specialty drug firm Alliance Pharma (AIM: APH) has acquired the antimalarial brands Paludrine, Avloclor and Savarine from Anglo-Swedish drug major AstraZeneca (LSE: AZN). The acquired products are sold mainly in the UK and France. 2 August 2012
Biotechnology
The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG greater than or equal to 500mg/dL) hypertriglyceridemia (very high triglycerides). 30 July 2012
Pharmaceutical
Germany-based Fresenius Kabi, a provider of infusion therapy and clinical nutrition, has reached a definitive agreement to acquire the US firm Fenwal, a company specializing in separation technologies for blood and cell collection and therapy. The acquisition, which is subject to customary conditions, is expected to be completed by the end of the year. Financial terms of the deal were not disclosed. 23 July 2012
Biotechnology
USA-based biopharma groups Synergy Pharmaceuticals (Nasdaq: SGYP) and Callisto Pharmaceuticals (OTCBB: CLSP) entered into a definitive merger agreement pursuant to which Callisto will merge into Synergy. 22 July 2012
Biotechnology
Pressures felt in Japan as a result of the country's aging population, drug price revisions and patent expiries have compelled pharmaceutical industry leaders to rationalize their sourcing and distribution, and increase operational efficiency, according to a new report by GBI Research, which states that market competition has led to a monopoly being held by a few wholesalers, who effectively control the country's pharmaceutical distribution market. 19 July 2012
Biotechnology
German biotech firms SYGNIS Pharma AG (Frankfurt: LIOK) and GENETRIX have signed a binding term sheet under which the companies propose to combine the GENETRIX' DNA sequencing subsidiary X-Pol Biotech and SYGNIS, with the goal of developing and marketing X-Pol Biotech's DNA sequencing technologies and products. 19 July 2012
Biotechnology
Confirming weekend rumors (The Pharma Letter July 16), UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday confirmed it has managed to do a deal with US partner Human Genome Sciences (Nasdaq: HGSI) to acquire the company by increasing its hostile tender offer from $13 to $14.25 per share in cash. 17 July 2012
Generics
The USA's Federal Trade Commission said yesterday that it will require Swiss drug major drug Novartis (NOVN: VX) to give up its marketing rights to four topical skin care products, under a proposed settlement resolving charges that the company's acquisition of private equity-owned generics firm Fougera Holdings would harm competition in the market for these topical drugs. 17 July 2012
Generics
Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals, has entered into a definitive merger agreement to be acquired by an affiliate of private investment company TPG in a transaction with an equity value of $1.9 billion. 17 July 2012
Generics
USA-based CritiTech and privately-held Indian group Finoso Pharma have formally established a joint venture which will be named Finotech Pharma with a business office in Lawrence, Kansas, USA. 16 July 2012
Biotechnology
Swiss biotechnology investment fund BB Biotech (SIX: BION) has confirmed that Vontobel Group has made a proposal to restructure BB Biotech from its current status as a listed investment company into an unlisted investment fund. Vontobel said the offer to take the firm private is a 31.7% premium to the 81.95 Swiss francs BB Biotech share price on July 12. 16 July 2012
Biotechnology
UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) announced on Friday that they had submitted regulatory applications in the USA and European Union for the once-daily investigational medicine fluticasone furoate and vilanterol (FF/VI) for patients with chronic obstructive pulmonary disease (COPD) and a regulatory application for asthma in the European Union. 16 July 2012
Generics
Agila Specialties Pharma Canada, which is part of the injectable drug division of Indian generic drugmaker Strides Arcolab (BO: 532531), has formed a joint venture with Jamp Pharma, a Canadian generic drug company, to introduce a variety of injectable generic drugs in Canada. 16 July 2012
Biotechnology
Spanish health care group Grifols (GRLS: MC), the world's third largest plasma product manufacturer, has acquired 40% of the equity of Catalan biotechnology firm VCN Biosciences, dedicated to the R&D of new therapeutic approaches for tumors for which there is no effective treatment. Financial terms of the transaction were not disclosed. 16 July 2012
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze